Janssen Biotech Inc.

10/25/2021 | Press release | Distributed by Public on 10/25/2021 06:37

New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease[...]